ABVX Abivax SA

DGAP-News: Abivax announces the release of its 2020 half-year financial report

DGAP-News: ABIVAX / Key word(s): Half Year Results
Abivax announces the release of its 2020 half-year financial report

30.09.2020 / 18:00
The issuer is solely responsible for the content of this announcement.

Abivax announces the release of its 2020 half-year financial report


PARIS, France, September 30, 2020 - 06:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announces the publication of its 2020 half-year financial report. This document is available in electronic version on the website of the company () and on the website of the French financial markets authority, AMF ().


About Abivax ()
Abivax, a clinical stage biotechnology company, is mobilizing the body's natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Abivax is listed on Euronext compartment C (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.

More information on the company is available at . Follow us on Twitter @ABIVAX_.

******

Contacts

Abivax
Finance Department
Didier Blondel

41		 Investors
LifeSci Advisors
Chris Maggos

 Press Relations & Investors Europe
MC Services AG
Anne Hennecke

22

Public Relations France
Actifin
Ghislaine Gasparetto

24
Public Relations France
DGM Conseil
Thomas Roborel de Climens

84
Public Relations USA
Rooney Partners LLC
Marion Janic

30.09.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

1137910  30.09.2020 

fncls.ssp?fn=show_t_gif&application_id=1137910&application_name=news&site_id=research_pool
EN
30/09/2020

Underlying

ABVXAbivax SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abivax SA

Tobias Fahrenholz
  • Tobias Fahrenholz
BUCN BUCHER INDUSTRIES AG
MERY MERCIALYS SA
RHK RHON-KLINIKUM AG
ABVX ABIVAX SA
FAGR FAGRON SA
UBS UBM DEVELOPMENT AG
ALD ALD SA
OVH OVH GROUPE
FERGR FERRARI GROUP PUBLIC LIMITED COMPANY
04/09/26 April 9, 2026 1 EN
Tobias Fahrenholz
  • Tobias Fahrenholz
BUCN BUCHER INDUSTRIES AG
MERY MERCIALYS SA
RHK RHON-KLINIKUM AG
ABVX ABIVAX SA
FAGR FAGRON SA
UBS UBM DEVELOPMENT AG
ALD ALD SA
OVH OVH GROUPE
FERGR FERRARI GROUP PUBLIC LIMITED COMPANY
04/09/26 April 9, 2026 1 FR
Martial Descoutures
  • Martial Descoutures
ABVX ABIVAX SA

Abivax : Pourquoi la maladie de Crohn est-elle un enjeu majeur pour Ab...

À ce stade, l’intérêt spéculatif autour d’Abivax semble encore largement être orienté par obefazimod dans la rectocolite ulcéreuse (RCH). Cependant, la maladie de Crohn pourrait constituer un levier de croissance supplémentaire majeur, susceptible d’élargir significativement le marché adressable et d’augmenter l’attractivité stratégique du programme. Dans cette perspective, le read-out de l’étude ENHANCE-CD, attendu au S2 26, représente l’un des catalyseurs les plus importants sur le titre. Nous...

04/09/26 April 9, 2026 1 FR
Martial Descoutures
  • Martial Descoutures
ABVX ABIVAX SA

Abivax : Why does Crohn's disease represent a major opportunity for Ab...

At this stage, speculative interest in Abivax still appears to be largely focused on obefazimod in ulcerative colitis (UC). However, Crohn's disease could represent a major additional growth driver, likely to significantly expand the addressable market and increase the strategic appeal of the programme. With this in mind, the read-out of the ENHANCE-CD study, expected in H2 2026, will be one of the most important catalysts on the project. We maintain our Outperform recommendation.

04/09/26 April 9, 2026 1 EN
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax Publishes Financial Reports with the French and U.S. Securities...

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – April 1, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”),  a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chr...

April 1, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch